BACKGROUND: Runt-related transcription factor 2 (RUNX2) is a transcription factor that is closely related to bone formation, and prostate cancer (CaP) is the most common cancer to metastasize to bone. The present study investigated the expression levels of RUNX2 in human prostate tissue, and the correlation between RUNX2 levels and the clinicopathological characteristics of CaP. METHODS: A case-control study was conducted including 114 cases of newly diagnosed CaP and 114 age-matched BPH patients as controls. RUNX2 expression was estimated using real-time PCR and immunohistochemical staining. RESULTS: The mRNA expression of RUNX2 did not differ between CaP tissues and non-cancer BPH controls (P ¼ 0.825). However, RUNX2 expression was significantly decreased in patients with elevated PSA levels (X20 ng ml À 1 ), a Gleason score X8 and metastatic disease compared to those with low PSA, low Gleason score and non-metastatic disease (P ¼ 0.023, 0.005 and 0.014, respectively). Immunohistochemical analysis showed that 65.2% of the patients with positive RUNX2 nuclear staining had metastatic disease, which was present in only 25.9% of those with negative staining (P ¼ 0.010). CONCLUSIONS: RUNX2 mRNA expression was negatively correlated with CaP aggressiveness. Moreover, the nuclear location of RUNX2 may be a prognostic marker of metastasis in CaP.
INTRODUCTION
Runt-related transcription factors (RUNX) determine cell fate and regulate lineage-specific proliferation and differentiation.
1,2 The RUNX gene family, which has been studied extensively, includes RUNX1, RUNX2 and RUNX3, closely related transcription factors that have crucial roles in both oncogenic and tumor-suppressive functions. RUNX1 is important for hematopoiesis and its ablation leads to leukemia, and RUNX3 is a critical regulator and its promoter hypermethylation is associated with several types of cancer. [3] [4] [5] [6] These findings strongly suggest that RUNX1 and RUNX3 function as tumor suppressors. The RUNX2 gene, on the other hand, is a unique member of the RUNX family that was shown to have a dual function in several studies. RUNX2 is a transcription factor essential for osteoblast differentiation, 7, 8 and its ablation results in deregulated cell proliferation and immortalization, supporting its function as a tumor suppressor. [9] [10] [11] However, several studies report that RUNX2 is upregulated in prostate and breast cancer cells that metastasize to bone, indicating a correlation with cancer progression, 12, 13 and therefore an oncogenic function for RUNX2.
RUNX2 is closely related to bone formation, and prostate cancer (CaP) is the most common cancer to metastasize to bone. Therefore, several studies focus on the role of RUNX2 in the tumor and bone tissue environments by using cell lines derived from metastatic bone lesions. Only a few studies have used human tissues to investigate the function of RUNX2 in CaP, and these studies report contradictory results. 1, 6, 14 Therefore, the present study was designed to investigate the expression levels of RUNX2 in human prostate tissue through a retrospective age-matched case-control study, and to examine the correlation between RUNX2 levels and the clinicopathological characteristics of CaP.
MATERIALS AND METHODS

Study population and tissue samples
A case-control study was conducted that included 114 Korean patients of newly diagnosed CaP and 114 controls selected from age-matched BPH patients. Patients who underwent radical prostatectomy or palliative TURP were included in the study, and all tissues were histologically confirmed to primary adenocarcinoma of the prostate at our institution. Patients who received neoadjuvant therapies such as androgen deprivation or radiation therapy were excluded in the current study. Controls were selected from the database of BPH patients who underwent TURP, and were one-to-one matched to cases according to age and the closest date of operation. Controls underwent TURP due to severe lower urinary tract symptoms or urinary retention even after proper medications. All tumors were macrodissected, typically within 15 min of surgical resection. Each specimen was confirmed by analysis of adjacent tissue in fresh-frozen sections from surgical specimens. In case of TURP, specimens were selected from relatively less injured tissues from electrical damage. The pathology samples were re-examined by a pathologist to confirm the presence of tumor or normal tissue. Controls with serum PSA levels higher than 3 ng ml À 1 underwent a transrectal prostate biopsy before TURP to rule out the presence of cancer. Gleason grades and TNM 2002 stage were used as prognostic factors. Gleason grades were assigned to the specimens obtained from 12-core transrectal biopsies, TURP or radical prostatectomy. Tumor stage was estimated from the specimens of the radical prostatectomy, or from the computed tomography, magnetic resonance image or bone scan results. The collection and analysis of all samples was approved by the Institutional Review Board of Chungbuk National University, and written informed consent was obtained from each subject (IRB approval number 2006-01-001).
RNA extraction and cDNA synthesis Total RNA was isolated from prostate tissue using 1 ml of TRIzol (Invitrogen, Carlsbad, CA, USA). The tissue was homogenized in a 5-ml glass tube. The homogenate was transferred to a 1.5-ml tube and then mixed with 200 ml of chloroform. Following incubation for 5 min at 4 1C, the homogenate was centrifuged for 13 min at 13 000 g at 4 1C. The upper aqueous phase was transferred to a clean tube to which 500 ml of isopropanol was added. Following incubation for 60 min at 4 1C and centrifugation for 8 min at 13 000 g at 4 1C, the upper aqueous phase was discarded and mixed with 500 ml of 75% ethanol, and then centrifuged for 5 min at 13 000 g at 4 1C. After discarding the upper aqueous layer, the pellet was dried at room temperature, dissolved in diethylpyrocarbonate-treated water and then stored at À 80 1C. The quality and integrity of the RNA were confirmed by agarose gel electrophoresis and ethidium bromide staining followed by visual inspection under ultraviolet light. The cDNA was prepared using 1 mg of random primers and a First-Strand cDNA Synthesis Kit (Amersham Biosciences Europe, Freiburg, Germany), according to the manufacturer's protocol.
Real-time PCR
To quantify the expression of RUNX2, real-time PCR was performed using a Rotor Gene 6000 instrument (Corbett Research, Mortlake, Australia). Realtime PCR assays were carried out in micro-reaction tubes (Corbett Research) using SYBR Premix EX Taq (Takara Bio, Otsu, Japan). The primers used for amplification of RUNX2 (182 bp) were as follows: sense, 5 0 -ACTGGCGCTGCAACAAGACC-3 0 and antisense, 5 0 -GCCCACAAATCTCA-GATCGT-3 0 . The PCR reaction was performed in a final volume of 10 ml containing 5 ml of 2 Â SYBR Premix EX Taq buffer, 0.5 ml of each of the sense and antisense primers (10 pmol ml À 1 ) and 1 ml of the sample cDNA. Amplified products were purified with a QIAquick Extraction kit (Qiagen, Hilden, Germany) and quantified with a spectrophotometer (Perkin Elmer MBA2000, Fremont, CA, USA). Fragments were sequenced using an automated laser fluorescence sequencer (ABI PRISM 3100 Genetic Analyzer, Foster City, WI, USA). Tenfold serial dilutions were prepared to obtain known concentrations of product in the range of 100 to 0.1 pg ml À 1 . The dilution series was used to establish a standard curve for real-time PCR. The real-time PCR conditions were as follows: (i) denaturation, 1 cycle of 20 s at 96 1C followed by 40 cycles of 2 s at 96 1C; (ii) annealing, 15 s at 60 1C; and (iii) extension, 15 s at 72 1C. The melting program was performed at 72-95 1C with a heating rate of 1 1C per 45 s. Spectral data were captured and analyzed using Rotor-Gene Real-Time Analysis Software 6.0 Build 14 (Corbett Research). All samples were run in triplicate. GAPDH was analyzed in parallel as an endogenous RNA reference gene and data were normalized to the expression of GAPDH.
Immunohistochemical staining
Paraffin blocks from 50 CaP cases and 10 BPH controls were used for immunohistochemical analysis. Tissue sections were cut and placed on SuperfrostPlus microscope slides (Fisher Scientific, Cheongju, South Korea). Using the Benchmark XT automated immunohistochemistry stainer (Ventana Medical Systems, Tucson, AZ, USA), tissues were stained as follows. Detection was done using the Ventana Ultraview DAB Kit (Ventana Medical Systems). Sections were deparaffinized using EZ Prep solution. CC1 standard (pH 8.4 buffer contained Tris/Borate/EDTA) was used for antigen retrieval. DAB inhibitor (3% H 2 O 2 , endogenous peroxidase) was blocked for 4 min at 37 1C temperature. Sections were incubated with an anti-RUNX2 primary antibody (Abcam, San Diego, CA, USA) for 40 min at 37 1C, and a secondary antibody of Univeral HRP Multimer for 8 min at 37 1C. Slides were stained with DAB þ H 2 O 2 substrate for 8 min followed by hematoxylin and bluing reagent counterstain at 37 1C. Reaction buffer (pH 7.6 Tris buffer) was used as washing solution. Staining intensity and proportion of positively stained epithelial cells were evaluated. RUNX2 localized primarily to the cytoplasm. Staining intensity was classified as follows: none, weak, moderate and strong. Each specimen was examined and scored separately by three investigators, and discrepancies were discussed until agreement was reached.
Statistical analysis
Clinical variables such as age and prostate size in patients and control groups were compared using the unpaired Student's t-test. The mRNA expression and PSA level were compared with clinical parameters using nonparametric analysis because expression data were not distributed normally and could not always be transformed to achieve normality for all analysis situations. Statistical analysis was performed using SPSS 19.0 software (SPSS, Chicago, IL, USA) and a Po0.05 was considered statistically significant. Table 1 shows the baseline characteristics of the 114 CaP patients and 114 BPH controls included in the study. The mean age of CaP patients was 68.9 years (range 51-84) and that of the BPH controls was 68.8 years (range 48-87). The serum PSA level was higher in CaP patients than in BPH cases (108.1 ± 382.3 ng ml À 1 vs 4.5 ± 5.9; Po0.001), but the size of the prostate was similar in both the groups (37.4 ± 22.6 g in controls and 42.3 ± 22.5 g in CaP patients; P ¼ 0.119). Of the 114 CaP patients, 54 (47.4%) underwent radical prostatectomy using open or laparoscopic procedures. The number of subjects with a Gleason score p7 andX8 was 51 (44.7%) and 63 (55.3%), respectively. Patients with stage T4 or less and metastatic disease were 61 (53.5%) and 53 (46.5%), respectively. The expression of RUNX2 in specimens did not differ between CaP and non-cancer BPH controls (P ¼ 0.825).
RESULTS
Baseline characteristics
RUNX2 expression levels according to clinical characteristics of cancer patients Table 2 shows the expression levels of RUNX2 according to clinicopathological characteristics. RUNX2 mRNA expression was significantly decreased in patients with elevated PSA levels (X20 ng ml In addition, RUNX2 expression was significantly lower in cancer specimens from patients with a higher Gleason score (X8) and metastatic disease than in those with a lower Gleason score (p7) and non-metastatic disease (P ¼ 0.005 and 0.014, respectively).
Immunohistochemical staining of RUNX2 in cancer and BPH tissues The presence of the RUNX2 protein was assessed in 10 BPH and 50 CaP samples by immunohistochemical staining (Figure 1 ). All BPH tissues (10/10) showed moderate to strong cytoplasmic staining for the RUNX2 protein, whereas various intensities of RUNX2 cytoplasmic staining were observed in epithelial and stromal cells in cancer tissues. Differences in cytoplasmic intensity between BPH and CaP tissues were not observed (P ¼ 0.074; Table 3 ). However, cytoplasmic staining for RUNX2 showed good correlation with RUNX2 mRNA expression (r ¼ 0.643, Po0.001). In terms of nuclear staining of RUNX2, BPH and cancer tissues showed different patterns. In BPH tissues, nuclear expression was always observed in basal cells and showed a heterogeneous pattern in luminal and stromal cells. However, only 46.0% (23/50) showed positive nuclear staining in cancer tissues. Interestingly, 65.2% (15/ 23) of the patients with nuclear location of RUNX2 had metastatic disease, whereas only 25.9% (7/27) of tissues with negative nuclear staining were associated with metastasis (P ¼ 0.010; Table 4 ). Also, the patients with positive nuclear staining had higher PSA levels than those with negative (57.9±128.2 ng ml 
DISCUSSION
The analysis of RUNX2 mRNA and protein levels in the present study revealed that transcriptional repression of RUNX2 in primary cancer tissues is associated with signs of aggressive disease such as an elevated PSA level, a high Gleason score and metastatic disease. RUNX2 is a transcription factor that is essential for osteoblast differentiation, 7, 8 and numerous studies have focused on its role in bone-related diseases. Therefore, the roles of RUNX2 in disease In BPH tissues, moderate to strong cytoplasmic RUNX2 expression was detected in epithelial cells, whereas nuclear expression was always observed in basal cells and showed a heterogeneous pattern in luminal and stromal cells (a, Â 200 magnification; b, Â 400 magnification). In cancer tissues, various intensities of RUNX2 cytoplasmic staining were observed in epithelial and stromal cells. In 23 of the 50 CaP specimens, RUNX2 nuclear expression was detected with either weak or strong staining intensities (c, weak stain in the cytoplasm with absent nuclear staining; d, strong stain in both cytoplasm and nucleus), and nuclear location of the RUNX2 protein was associated with metastatic disease ( Â 200 magnification). CaP, prostate cancer; RUNX2, runt-related transcription factor 2.
progression or metastasis have been examined in both prostate and breast cancer, which frequently metastasize to bone. [14] [15] [16] Cell line studies using PC-3 and C4-2B cells, which were isolated from metastatic bone lesions, demonstrated that RUNX2 upregulation is related to metastatic potential. 17 Furthermore, Brubaker et al.
14 investigated the role of RUNX2 in the growth and survival of CaP cells in bone using cell lines and human tissues, and demonstrated that RUNX2 mRNA levels were higher in PC-3 than in LNCaP cells. However, in human samples, RUNX2 expression was observed in normal prostate and primary CaP samples from 11 patients, although the detailed results of RT-PCR were not reported. Our investigation was conducted using 114 tissue specimens of each, CaP cases and age-matched controls, and clearly showed that although no differences in RUNX2 mRNA expression were detected between CaP and BPH tissues, RUNX2 downregulation was significantly associated with advanced disease compared with less advanced cases. To date, the current study is the largest scale experiment of RUNX2 expression using human specimens, and the present results suggest that RUNX2 may have a role in CaP as a suppressor of a more aggressive tumor phenotype. These findings are not in accord with previous studies using cell lines. Although the exact reason for this disparity is not clear, the composition of cancer tissues, which includes several types of cells including cancer, epithelial, stromal and inflammatory cells, and the crosstalk between them, should be taken into consideration. Moreover, cancer tissues obtained from the prostate did not contain a bone component, suggesting that the role of RUNX2 in metastatic bone lesions may be different from that indicated by our results in terms of RUNX2 as a regulator of the microenvironment for surviving cancer cells in bone. To confirm this hypothesis, we attempted to obtain metastatic bone tissues, which unfortunately were not available in our hospital. Immunohistochemical staining to evaluate RUNX2 protein levels in CaP yielded results that were somewhat inconsistent with those of previous studies. Chua et al. 18 analyzed RUNX2 protein levels in specimens from 39 BPH patients, 8 high-grade prostatic intraepithelial neoplasia cases and 128 CaP tissues by immunohistochemical staining. These authors reported that RUNX2 was undetectable or showed low cytoplasmic expression in BPH (2.6%), whereas the protein was detected in the cytoplasm in 84.4% of CaP tissues, which is contrary to our results. In addition, no correlation between cytoplasmic expression of RUNX2 and prognostic significance was reported in their study. In another study, Akech et al. 13 analyzed a CaP tissue microarray using immunohistochemistry and reported that the majority of non-neoplastic tissues and prostatic intraepithelial neoplasia lesions were negative for RUNX2, whereas 48% of the primary tumors and 46% of metastatic tissues were RUNX2 positive. In contrast to these two reports, cytoplasmic RUNX2 protein expression in the present study was consistently observed in all BPH tissues with similar patterns of staining with moderate to strong intensity. The correlation was also observed between RUNX2 mRNA expression and the cytoplasmic staining intensity of the protein. Similar immunohistochemical findings to those of the current study were reported by Brubaker et al., 14 who analyzed human prostate tissues obtained from 16 radical prostatectomies and 12 rapid autopsy specimens, and reported the detection of the RUNX2 protein in both CaP cells and normal glands. The immunohistochemical findings of the current study may be inconclusive because only 50 CaP and 10 BPH tissue specimens as controls were used for the analysis. Therefore, further study with a larger sample size is necessary to draw a more convincing conclusion in this particular aspect.
Interestingly, nuclear localization of RUNX2 was significantly associated with metastatic disease compared with the cases in which RUNX2 was not detected in the nucleus, which is in agreement with the results reported by Chua et al. 18 According to their study, RUNX2 nuclear expression was associated with a higher Gleason score (X7), higher PSA levels (X20 ng ml À 1 ) and an increased risk of metastasis. These results suggested that nuclear expression of RUNX2 could be used as a prognostic marker to predict metastasis in advanced CaP, although further studies are required to confirm this hypothesis.
In conclusion, RUNX2 mRNA expression was negatively correlated with CaP aggressiveness as reflected by elevated PSA levels, a higher Gleason score and metastatic disease. Moreover, nuclear location of RUNX2 could be an important prognostic marker to predict metastasis in CaP.
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